Ser. No. 08/182,183

wherein said nucleic acid sequence encodes a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:4 or SEQ ID NO:6, wherein said nucleic acid sequence is operatively linked to a non-native promoter, and wherein said polypeptide has the capability to promote dopamine uptake in dopaminergic neurons.

161. (Twice Amended) An isolated [A transformed or transfected] host cell which expresses a nucleic acid sequence encoding a glial cell line-derived neurotrophic factor polypeptide, wherein said nucleic acid sequence encodes a polypeptide comprising an amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, wherein said nucleic acid sequence is operatively linked to a non-native promoter, and wherein said encoded polypeptide has the capability to promote dopamine uptake in dopaminergic neurons.

REMARKS

Claims 88-92, 94, 117-161 and 165-177 are pending in the application. Claims 88-94, 118-120, 135, 150 and 152-157 were previously allowed. Allowed claims in the presently addressed Office Action are 88, 118-120, 124-125, 150-152, 154-157, 165-171 and 175.

Claims 91, 137, 139 and 176-177 were objected to as being dependent upon a rejected base claim, but were said to be allowable if rewritten in independent form. Claim 91 has been canceled. Claim 137, which was dependent on now canceled claim 136 has been rewritten as suggested by the Examiner. Claim 138 has been amended as suggested by the Examiner to indicate "an isolated" host cell. Thus, dependent claim 139 should now be allowable. Claim 94 has been amended as suggested by the Examiner to indicate "bacterial" production. Thus, dependent claim 176 should now be allowable. Claim 137 was rewritten as stated above, and therefore dependent claim 177 should now be allowable.

Claim 136 has been canceled and therefore the rejection is rendered moot.

Claims 90, 127-128, 133-135, 138, 140-142, 144 and 159-161 were rejected as failing to recite an isolated cell. Claims 90, 127, 135, 138 and 159-161 have been amended as suggested by the Examiner, and therefore, the rejection may properly be withdrawn for these claims and the

Ser. No. 08/182,183

dependent claims. Claim 92 was canceled.

Claims 89-90, 92, 94, 117, 121-123, 126-134, 143-149, 153, 158 and 172-174 were rejected as failing to indicate bacterial expression and/or the use of a final washing condition as recited on page 63 of the specification. Claims 89-90, 94, 117, 121 and 153 have been amended as suggested by the Examiner with washing conditions taken directly from the specification, and therefore, the rejection may properly be withdrawn for these claims and the dependent claims.

For the foregoing reasons and in view of the amendments, Applicants respectfully request entry of the amendments and withdrawal of the outstanding rejections. Applicants' representative would appreciate the opportunity to talk with the Examiner, in person or by telephone, to discuss any remaining questions and facilitate the prosecution and allowance of the application or to place the case in better form for appeal.

Respectfully submitted,

Daniel R. Curry

Attorney for Applicants Registration No: 32,727

Phone: (805) 447-8102

Date: July 9, 1999

Please send all future correspondence to:

U.S. Patent Operations/DRC M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799